Lead Biologics is focused on developing targeted immunotherapies for cancer using proprietary biologic agents that enhance the immune system's ability to identify and destroy tumor cells. This approach aims to improve treatment efficacy while minimizing side effects associated with traditional cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often fail to completely eradicate tumors or can cause significant side effects due to a lack of specificity. There is a need for more targeted therapies that can effectively eliminate cancer cells while minimizing harm to healthy tissues.
Solution
Lead Biologics is developing a pipeline of targeted immunotherapies designed to enhance the immune system's ability to recognize and destroy cancer cells. The company focuses on identifying novel therapeutic targets and developing first-in-class antibody treatments. By combining expertise in recombinant antibody technology and state-of-the-art experimental models, Lead Biologics aims to provide proof-of-concept for novel treatments. Their approach seeks to improve treatment efficacy and reduce the adverse effects associated with traditional cancer therapies. Lead Biologics is also open to academic and industrial collaborations to bring projects to patients efficiently.
Target Audience
Lead Biologics' primary target audience includes patients with leukemia and solid tumors, as well as pharmaceutical companies seeking innovative cancer therapies.
Features
- LB01: Antibody targeting SLAMF6, a novel immune checkpoint, to enhance T cell-mediated elimination of cancer cells in leukemia and solid tumors.
- LB02: Antibody targeting C3AR, a marker selectively expressed on leukemic stem cells, allowing for specific targeting in AML and solid tumors without affecting normal hematopoietic stem cells.
- LB03: Antibody targeting a novel "don't eat me" signal regulating macrophage function, inducing phagocytosis in AML and solid tumors, with no expression in healthy hematopoietic stem cells.
- Discovery of novel targets based on academic excellence.
- Development of therapeutic antibodies against cancer.